DNA-Binding Natural Product Peptides Repurposed as Antibody-Drug Conjugate Payloads for Targeted Cancer Therapy | Research

The takeaway

Synthetic analogs of DNA bis-intercalating natural product peptides were developed as potent antibody-drug conjugate payloads, with site-specific conjugation producing well-tolerated, highly effective anticancer agents in mice.

THIOMAB DAR2: well-tolerated and highly efficacious
Site-specific conjugation of bis-intercalating peptide payloads at DAR2 achieved both safety and potent antitumor activity in mice, while DAR4 was toxic

What the researchers found

34 novel synthetic analogs of DNA bis-intercalating peptides were synthesized and characterized. Initial ADC constructs were hydrophobic and aggregation-prone. Two strategies improved properties: solubilizing linker groups and enzymatically cleavable hydrophilic masks. All ADCs showed potent in vitro cytotoxicity in high-antigen-expressing cells. Masked ADCs were less potent in low-antigen cell lines. In vivo, stochastically conjugated DAR4 anti-FRα ADCs were toxic at low doses, while site-specific THIOMAB DAR2 anti-cMet ADCs were well-tolerated and highly efficacious — demonstrating that conjugation strategy critically affects the therapeutic window.

Why it matters

ADCs are among the fastest-growing class of cancer drugs, with over a dozen approved. Finding new, potent payloads is critical because current options (auristatins, maytansinoids) face resistance in some tumors. DNA-intercalating peptides represent a mechanistically distinct payload class that kills cells differently — by disrupting DNA structure directly. The optimization work on conjugation chemistry and masking strategies addresses the key practical challenges of making peptide-based payloads clinically viable.

How the study worked

Researchers synthesized 34 analogs of sandramycin and quinaldopeptin-based bis-intercalating peptides using medicinal chemistry approaches. Biophysical characterization assessed DNA binding and physicochemical properties. In vitro cytotoxicity was tested across cancer cell lines with varying antigen expression. Drug-linker chemistry was optimized using solubilizing groups and cleavable masks. Two in vivo pilot studies compared stochastic (DAR4) versus site-specific (THIOMAB DAR2) conjugation strategies.

What this study cannot tell us

Only two pilot in vivo studies were conducted, providing preliminary efficacy and tolerability data. The DAR4 anti-FRα ADC showed dose-limiting toxicity even at low doses, indicating a narrow therapeutic window for some configurations. Masked ADCs showed reduced potency in low-antigen cell lines, which could limit their use in heterogeneous tumors. Long-term efficacy, pharmacokinetics, and safety profiles were not characterized. No clinical data exist.

How to read the evidence

This is a preclinical medicinal chemistry and drug development study with in vitro potency data and two pilot in vivo studies. The 34-analog SAR campaign is thorough, but clinical translatability remains to be demonstrated.

When this study was published

Published in 2023 in the Journal of Medicinal Chemistry, this represents current work at the frontier of ADC payload development using peptide-based natural product analogs.

The bigger picture

The ADC field is rapidly expanding beyond traditional payloads. Natural product peptides that bind DNA represent an untapped source of cancer-killing molecules. This study demonstrates that medicinal chemistry can overcome the typical challenges of peptide-based ADC payloads (hydrophobicity, aggregation) through smart linker design and masking strategies. The success of THIOMAB site-specific conjugation also highlights how precision engineering of the antibody-drug linkage is as important as the payload itself.

Questions still open

Can the therapeutic window of bis-intercalating peptide ADCs be further widened through linker optimization or alternative masking strategies?
How do DNA bis-intercalating peptide payloads compare to current ADC payloads (auristatins, maytansinoids) for treating payload-resistant tumors?
Would combination of these ADCs with immune checkpoint inhibitors enhance antitumor efficacy?

Common questions

What is an antibody-drug conjugate and how do peptide payloads fit in?

Antibody-drug conjugates (ADCs) are targeted cancer therapies: an antibody finds and binds to a specific marker on cancer cells, then releases a toxic 'payload' inside the cell to kill it. Most current payloads are small molecules, but this study used synthetic peptides derived from natural products that kill cells by wedging into DNA and disrupting its structure. These peptide payloads offer a different killing mechanism that could work against cancers resistant to current ADC drugs.

Why does it matter how the drug is attached to the antibody?

The way a payload is linked to the antibody dramatically affects both safety and effectiveness. This study showed that attaching four peptide payloads randomly to the antibody (DAR4, stochastic) produced a construct that was toxic even at low doses. But precisely attaching two payloads at specific sites on the antibody (THIOMAB DAR2) was both well-tolerated and highly effective. This demonstrates that precision engineering of the antibody-drug connection is just as important as the payload itself.

Read the original research

Structure-Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody-Drug Conjugate Payloads.

Journal of medicinal chemistry, 66(12), 8288-8309

View on PubMed ↗Publisher’s paper ↗

Citation

Petersen, Mark E; Brant, Michael G; Lasalle, Manuel; Fung, Vincent K C; Rojas, Andrea Hernandez; Wong, Jodi; Das, Samir; Barnscher, Stuart D; Rich, Jamie R; Winters, Geoffrey C. (2023). Structure-Activity Relationships of Bis-Intercalating Peptides and Their Application as Antibody-Drug Conjugate Payloads.. Journal of medicinal chemistry, 66(12), 8288-8309. https://doi.org/10.1021/acs.jmedchem.3c00760